Accessibility Menu
Arrow-Thin-Down
S&P 500
6,857.92
+1.0%
+66.23
Arrow-Thin-Down
DJI
47,403.60
+0.4%
+196.48
Arrow-Thin-Down
NASDAQ
23,594.62
+1.7%
+389.75
Arrow-Thin-Down
Bitcoin
$115,517.00
+1.7%
+$1,967.74
Arrow-Thin-Down
AAPL
$265.72
+1.1%
+$2.90
Arrow-Thin-Down
AMZN
$227.66
+1.5%
+$3.45
Arrow-Thin-Down
GOOG
$268.00
+2.9%
+$7.49
Arrow-Thin-Down
META
$749.93
+1.6%
+$11.57
Arrow-Thin-Down
MSFT
$531.42
+1.5%
+$7.81
Arrow-Thin-Down
NVDA
$191.75
+2.9%
+$5.49
Arrow-Thin-Down
TSLA
$457.51
+5.5%
+$23.79
Daily Stock GainersDaily Stock LosersMost Active Stocks
Oxurion Stock Quote

Oxurion (OTC: TBGNF)

Some price data may be temporarily unavailable.

KEY DATA POINTS

Current Price
$0.00
Daily Change
(-) $0.00
Day's Range
$0.00 - $0.00
Previous Close
$0.00
Open
$0.00
Beta
0
Volume
-
Average Volume
-
Sector
Health Care
Market Cap
-
Market Cap / Employee
-
52wk Range
$0.00 - $0.00
Revenue
-
Gross Margin
-
Dividend Yield
-
EPS
$0.00
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Oxurion Company Info

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium.

News & Analysis

Featured Article

ThromboGenics Plays Long Game for Eye Disease

ThromboGenics's expansion from the small neighborhood of vitreomacular adhesion to the big city of diabetic macular edema is a solid long term strategy for building is pipeline of ophthalmologic drugs.

Catherine Shaffer  |  Mar 26, 2014

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services